                         SEQUENCE LISTING

<110>  Vanderbilt University
 
<120>  HUMAN IgE MONOCLONAL ANTIBODIES TO ALPHA-GAL 
       (GALACTOSE-ALPHA-1,3-GALACTOSE) AND USES THEREFOR

<130>  VBLT.P0312WO

<140>  Unknown
<141>  2021-12-13

<150>  63/125,099
<151>  2020-12-14

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  349
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  1
caggtgcagc tacaacagtg gggcgcagga ctgttgaagc catcggagac cctgtccctc       60

acctgcgctg tctatggtgg gacgttcagt gattacttct atacctggat ccgccagccc      120

ccagggaagg ggctggagtg gattggggaa gtcagtcata ctgggaggac cagctacatc      180

ccgtccctca agagtcgagt caccatgtca gtagacacgt ctaaaaacca gttctccctg      240

aacttgagct ctgtgaccga cgcggacacg gctgtttatt attgtgggag aggtcggggt      300

tacacttgga atgattgggg ccagggaacg ctagtcaccg tctcctcag                  349


<210>  2
<211>  349
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  2
cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc       60

tcctgcactg gaaccatcac tgacgttggt ggttatgact atgtctcctg gtaccaacaa      120

cacccaggca aagcccccaa actcatcatt ttccttgtca ataatcggcc ctcaggggtt      180

tctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctcagggctc      240

cgggttgagg acgaggctga ttattattgc atgtcatata catgcagcaa cccatataca      300

tgcagcagcc tttatgtctt cggaactggg accaaggtca ccgtcctgg                  349


<210>  3
<211>  357
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  3
caggtgcagc tggtggagtc ggggggaggc gtggtccagc ctgggaggtc cctgagactc       60

tcctgtgcgg tgtctggatt caccttcagg agctttggca tgcactgggt ccgccaggct      120

ccgggcaagg ggctggagtg ggtggcagtc atatggcatg atggaagtaa caagcactat      180

gcagactccg tgaagggccg attcaccatt tccagagacg actccaagaa caccctgttt      240

ctgcaaatga acagcctgag agccgaggac acggctgtgt attattgtgc gagagaatcg      300

gaggaacagg gaaatatgga cgtctggggc caagggacca cggtcaccgt ctcctca         357


<210>  4
<211>  340
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  4
gatgttgtga tgactcagtc tccactctcc ctgcccgcca cccttggcca gccggcctcc       60

atctcctgca ggtctagtca tagcctcgtt tacagtaatg gaaacaccta cttgaattgg      120

tttcagcaga ggccaggcca atctccaagg cgcctgtttt ttcaggtttc taaccgggac      180

tctggggtcc cagacagatt cagcggcagt gggtccgtaa ctaatttcac actgaaaatc      240

agcagggtgg aggctgagga tgttggggtc tactactgca tggaaggttc acactggcct      300

ccgtacactt ttggccaggg gaccaggctg gacatcagac                            340


<210>  5
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  5

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Thr Phe Ser Asp Tyr 
            20                  25                  30          


Phe Tyr Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Val Ser His Thr Gly Arg Thr Ser Tyr Ile Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Asn Leu Ser Ser Val Thr Asp Ala Asp Thr Ala Val Tyr Tyr Cys Gly 
                85                  90                  95      


Arg Gly Arg Gly Tyr Thr Trp Asn Asp Trp Gly Gln Gly Thr Leu Val 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  6
<211>  116
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  6

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 
1               5                   10                  15      


Ser Ile Thr Ile Ser Cys Thr Gly Thr Ile Thr Asp Val Gly Gly Tyr 
            20                  25                  30          


Asp Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 
        35                  40                  45              


Ile Ile Phe Leu Val Asn Asn Arg Pro Ser Gly Val Ser Asp Arg Phe 
    50                  55                  60                  


Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 
65                  70                  75                  80  


Arg Val Glu Asp Glu Ala Asp Tyr Tyr Cys Met Ser Tyr Thr Cys Ser 
                85                  90                  95      


Asn Pro Tyr Thr Cys Ser Ser Leu Tyr Val Phe Gly Thr Gly Thr Lys 
            100                 105                 110         


Val Thr Val Leu 
        115     


<210>  7
<211>  119
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  7

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Arg Ser Phe 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp His Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Phe 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Glu Ser Glu Glu Gln Gly Asn Met Asp Val Trp Gly Gln Gly 
            100                 105                 110         


Thr Thr Val Thr Val Ser Ser 
        115                 


<210>  8
<211>  113
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  8

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Ala Thr Leu Gly 
1               5                   10                  15      


Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser His Ser Leu Val Tyr Ser 
            20                  25                  30          


Asn Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
        35                  40                  45              


Pro Arg Arg Leu Phe Phe Gln Val Ser Asn Arg Asp Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Val Thr Asn Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Glu Gly 
                85                  90                  95      


Ser His Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Asp Ile 
            100                 105                 110         


Arg 
    


<210>  9
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  9

Gly Gly Thr Phe Ser Asp Tyr Phe 
1               5               


<210>  10
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  10

Val Ser His Thr Gly Arg Thr 
1               5           


<210>  11
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  11

Gly Arg Gly Arg Gly Tyr Thr Trp Asn Asp 
1               5                   10  


<210>  12
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  12

Gly Phe Thr Phe Arg Ser Phe Gly 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  13

Ile Trp His Asp Gly Ser Asn Lys 
1               5               


<210>  14
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  14

Ala Arg Glu Ser Glu Glu Gln Gly Asn Met Asp Val 
1               5                   10          


<210>  15
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  15

Ile Thr Asp Val Gly Gly Tyr Asp Tyr 
1               5                   


<210>  16
<211>  16
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  16

Met Ser Tyr Thr Cys Ser Asn Pro Tyr Thr Cys Ser Ser Leu Tyr Val 
1               5                   10                  15      


<210>  17
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  17

His Ser Leu Val Tyr Ser Asn Gly Asn Thr Tyr 
1               5                   10      


<210>  18
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic antibody

<400>  18

Met Glu Gly Ser His Trp Pro Pro Tyr Thr 
1               5                   10  


